

Javier Cortes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1255878/publications.pdf>

Version: 2024-02-01

258
papers

26,550
citations

18436

62
h-index

6818

155
g-index

263
all docs

263
docs citations

263
times ranked

21937
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 165-182.	157.7	132
2	Targeting brain metastases in breast cancer. <i>Cancer Treatment Reviews</i> , 2022, 103, 102324.	3.4	46
3	Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 556-567.	13.9	444
4	AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210839.	1.4	16
5	Immunotherapy for early triple negative breast cancer: research agenda for the next decade. <i>Npj Breast Cancer</i> , 2022, 8, 23.	2.3	67
6	Differences in the Molecular Profile between Primary Breast Carcinomas and Their Cutaneous Metastases. <i>Cancers</i> , 2022, 14, 1151.	1.7	5
7	Gene signatures in patients with early breast cancer and relapse despite pathologic complete response. <i>Npj Breast Cancer</i> , 2022, 8, 42.	2.3	9
8	Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 1143-1154.	13.9	474
9	Evaluation of the TCR Repertoire as a Predictive and Prognostic Biomarker in Cancer: Diversity or Clonality?. <i>Cancers</i> , 2022, 14, 1771.	1.7	15
10	Elaestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 3246-3256.	0.8	190
11	Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Moving Into a New Era. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 82-92.	1.8	6
12	Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1000-1000.	0.8	9
13	Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	25
14	Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA1001-LBA1001.	0.8	68
15	nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR–, HER2– metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 195, 55-64.	1.1	3
16	nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, 181-190.e2.	1.1	23
17	Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188487.	3.3	16
18	The Global Landscape of Treatment Standards for Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1143-1155.	3.0	13

#	ARTICLE	IF	CITATIONS
19	Evolution of Angiogenic Factors in Pregnant Patients with Breast Cancer Treated with Chemotherapy. <i>Cancers</i> , 2021, 13, 923.	1.7	1
20	Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 3116-3125.	3.2	9
21	PI3K activation promotes resistance to eribulin in HER2-negative breast cancer. <i>British Journal of Cancer</i> , 2021, 124, 1581-1591.	2.9	12
22	Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 499-511.	5.1	260
23	Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 1529-1541.	13.9	601
24	Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 811-824.	1.4	16
25	Nobody dares stopping clinical research, not even COVID-19. <i>Npj Breast Cancer</i> , 2021, 7, 39.	2.3	0
26	Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase 3 trial. <i>European Journal of Cancer</i> , 2021, 148, 382-394.	1.3	22
27	Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (METRIC): a randomized multicenter study. <i>Npj Breast Cancer</i> , 2021, 7, 57.	2.3	26
28	Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer. <i>European Journal of Cancer</i> , 2021, 148, 134-145.	1.3	10
29	Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 858-871.	5.1	60
30	The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers. <i>Npj Breast Cancer</i> , 2021, 7, 73.	2.3	2
31	Epithelial Mesenchymal Transition and Immune Response in Metaplastic Breast Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7398.	1.8	13
32	Pembrolizumab plus chemotherapy in triple-negative breast cancer - Authors' reply. <i>Lancet</i> , The, 2021, 398, 24-25.	6.3	1
33	I-SPY2 platform: New lessons from the olaparib and durvalumab combination in breast cancer treatment. <i>Cancer Cell</i> , 2021, 39, 902-904.	7.7	0
34	Anthracyclines for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Are We Ready to Let Them Go?. <i>Journal of Clinical Oncology</i> , 2021, 39, 3541-3545.	0.8	6
35	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <i>Cancers</i> , 2021, 13, 4421.	1.7	12
36	Clinical, Pathological, and Molecular Features of Breast Carcinoma Cutaneous Metastasis. <i>Cancers</i> , 2021, 13, 5416.	1.7	7

#	ARTICLE	IF	CITATIONS
37	Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study. <i>Cancers</i> , 2021, 13, 5432.	1.7	4
38	CDK4/6 inhibitors in breast cancer: spotting the difference. <i>Nature Medicine</i> , 2021, 27, 1868-1869.	15.2	4
39	Epstein-Barr Virus+ B Cells in Breast Cancer Immune Response: A Case Report. <i>Frontiers in Immunology</i> , 2021, 12, 761798.	2.2	2
40	Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. <i>Npj Breast Cancer</i> , 2021, 7, 145.	2.3	9
41	Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110595.	1.4	10
42	HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. <i>Journal of the National Cancer Institute</i> , 2020, 112, 46-54.	3.0	97
43	Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 423-433.	0.8	240
44	Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 610-621.	13.9	1,143
45	Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 35-45.	3.2	22
46	Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: A post hoc pooled analysis. <i>Breast Journal</i> , 2020, 26, 1347-1351.	0.4	7
47	Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients. <i>Cancer Treatment Reviews</i> , 2020, 83, 101944.	3.4	3
48	Molecular Features of Metaplastic Breast Carcinoma: An Infrequent Subtype of Triple Negative Breast Carcinoma. <i>Cancers</i> , 2020, 12, 1832.	1.7	30
49	Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial. <i>Breast Cancer Research</i> , 2020, 22, 124.	2.2	21
50	Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. <i>Lancet</i> , The, 2020, 396, 1817-1828.	6.3	992
51	Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial. <i>Cancers</i> , 2020, 12, 3509.	1.7	7
52	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. <i>Lancet Oncology</i> , The, 2020, 21, 1455-1464.	5.1	52
53	Immunotherapy in Breast Cancer: Current Practice and Clinical Challenges. <i>BioDrugs</i> , 2020, 34, 611-623.	2.2	38
54	Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2+, Node-Positive, High-Risk, Early Breast Cancer (monarchE). <i>Journal of Clinical Oncology</i> , 2020, 38, 3987-3998.	0.8	478

#	ARTICLE	IF	CITATIONS
55	Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis. <i>Cancer Research</i> , 2020, 80, 5427-5434.	0.4	77
56	Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial. <i>Clinical Cancer Research</i> , 2020, 26, 5820-5829.	3.2	68
57	CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge. <i>Cancers</i> , 2020, 12, 2480.	1.7	15
58	Atezolizumab in the treatment of metastatic triple-negative breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 981-989.	1.4	20
59	Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019. <i>European Journal of Cancer</i> , 2020, 135, 62-65.	1.3	32
60	High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin [®] but not with treatment of physician [™] s choice [™] in the EMBRACE study. <i>Breast Cancer</i> , 2020, 27, 706-715.	1.3	41
61	Pembrolizumab for Early Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 810-821.	13.9	1,542
62	Enhancing global access to cancer medicines. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 105-124.	157.7	123
63	Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade. <i>Nature Communications</i> , 2020, 11, 385.	5.8	67
64	HER2-Low Breast Cancer: Pathological and Clinical Landscape. <i>Journal of Clinical Oncology</i> , 2020, 38, 1951-1962.	0.8	353
65	Lucitanib for the Treatment of HR+/HER2 ⁺ Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study. <i>Clinical Cancer Research</i> , 2020, 26, 354-363.	3.2	40
66	Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2 ⁺ Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6417-6428.	3.2	11
67	KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1000-1000.	0.8	135
68	PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER) [+]/HER2 [-] metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1007-1007.	0.8	34
69	Chemotherapy (CT) de-escalation using an FDG-PET/CT (F-PET) and pathological response-adapted strategy in HER2 [+] early breast cancer (EBC): PHERGain Trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 503-503.	0.8	22
70	Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1096-1104.	2.3	33
71	Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy. <i>Journal of the National Cancer Institute</i> , 2019, 111, 69-77.	3.0	60
72	POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2019, 25, 6598-6605.	3.2	17

#	ARTICLE	IF	CITATIONS
73	Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 1556.	3.4	62
74	Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer. <i>European Journal of Cancer</i> , 2019, 120, 1-9.	1.3	39
75	The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer. <i>Cell Reports</i> , 2019, 27, 2690-2708.e10.	2.9	95
76	IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. <i>Future Oncology</i> , 2019, 15, 1951-1961.	1.1	58
77	The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin. <i>Frontiers in Oncology</i> , 2019, 9, 193.	1.3	17
78	Hydrodynamic and Electrophoretic Properties of Trastuzumab/HER2 Extracellular Domain Complexes as Revealed by Experimental Techniques and Computational Simulations. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1076.	1.8	5
79	Immunotherapy for HER2-Positive Breast Cancer: Changing the Paradigm. <i>Current Breast Cancer Reports</i> , 2019, 11, 248-258.	0.5	2
80	Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study. <i>Clinical Breast Cancer</i> , 2019, 19, 105-112.	1.1	12
81	Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA. <i>Genome Medicine</i> , 2019, 11, 1.	3.6	84
82	Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials.. <i>Journal of Clinical Oncology</i> , 2019, 37, 571-571.	0.8	6
83	XENERA-1: A phase II trial of xentuzumab (Xe) in combination with everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and non-visceral involvement.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS1103-TPS1103.	0.8	3
84	KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS601-TPS601.	0.8	10
85	The new world of biosimilars in oncology: Translation of data to the clinic. <i>European Journal of Cancer</i> , 2018, 96, 125-127.	1.3	2
86	Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. <i>Lancet Oncology</i> , The, 2018, 19, 812-824.	5.1	98
87	Change in Topoisomerase I-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol. <i>Clinical Cancer Research</i> , 2018, 24, 3348-3357.	3.2	18
88	Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer. <i>Investigational New Drugs</i> , 2018, 36, 848-859.	1.2	55
89	Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer. <i>Cancer Treatment Reviews</i> , 2018, 63, 144-155.	3.4	26
90	Quality-Adjusted Survival With nab-Paclitaxel Versus Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis. <i>Clinical Breast Cancer</i> , 2018, 18, e919-e926.	1.1	9

#	ARTICLE	IF	CITATIONS
91	Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. <i>European Journal of Cancer</i> , 2018, 89, 27-35.	1.3	172
92	Spurring science, marking progress, and influencing history. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 79-80.	12.5	3
93	Reply to K.S. Shohdy et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 2458-2459.	0.8	0
94	Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3126-3133.	0.8	52
95	A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study. <i>Oncotarget</i> , 2018, 9, 35687-35704.	0.8	55
96	Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases. <i>Oncotarget</i> , 2018, 9, 20617-20630.	0.8	36
97	p95HER2- α T cell bispecific antibody for breast cancer treatment. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	59
98	CXCR4 antagonists for treatment of breast cancer. <i>Oncotarget</i> , 2018, 9, 33442-33443.	0.8	4
99	Multiple modes of action of eribulin mesylate: Emerging data and clinical implications. <i>Cancer Treatment Reviews</i> , 2018, 70, 190-198.	3.4	52
100	Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2. <i>European Journal of Cancer</i> , 2018, 103, 147-154.	1.3	52
101	Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. <i>Clinical Cancer Research</i> , 2018, 24, 5820-5829.	3.2	82
102	Extracellular HMGA1 Promotes Tumor Invasion and Metastasis in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 6367-6382.	3.2	52
103	SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (HR+ with or without letrozole) in trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS1101-TPS1101.	0.8	5
104	Contessa: A multinational, multicenter, randomized, phase 3 registration study of tasetaxel in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS1106-TPS1106.	0.8	1
105	KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS602-TPS602.	0.8	30
106	Phase III study of tasisib (GDC-0032) + fulvestrant (FULV) vs FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.. <i>Journal of Clinical Oncology</i> , 2018, 36, LBA1006-LBA1006.	0.8	116
107	KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (PBO) + chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS18-TPS18.	0.8	6
108	Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. <i>Clinical Cancer Research</i> , 2017, 23, 649-657.	3.2	108

#	ARTICLE	IF	CITATIONS
109	HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 545-554.	5.1	250
110	Role of total tumour load of sentinel lymph node on survival in early breast cancer patients. <i>Breast</i> , 2017, 33, 8-13.	0.9	34
111	MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2 ⁺ Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5218-5224.	3.2	492
112	Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 904-916.	5.1	427
113	Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 329-341.	1.1	40
114	Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial. <i>European Journal of Cancer</i> , 2017, 76, 205-215.	1.3	14
115	A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 535-544.	1.1	16
116	Advances in the management of HER2-positive early breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 119, 113-122.	2.0	42
117	Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 527-537.	3.3	59
118	The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies. <i>Cancer Treatment Reviews</i> , 2017, 61, 53-60.	3.4	39
119	The AURORA pilot study for molecular screening of patients with advanced breast cancer—a study of the breast international group. <i>Npj Breast Cancer</i> , 2017, 3, 23.	2.3	8
120	A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 601-609.	1.1	25
121	18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial. <i>Clinical Cancer Research</i> , 2017, 23, 1432-1441.	3.2	32
122	Overall survival (OS) in patients (Pts) with diagnostic positive (Dx+) breast cancer: Subgroup analysis from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in AR+ triple-negative breast cancer (TNBC) treated with 0-1 prior lines of therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1089-1089.	0.8	10
123	Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial. <i>SpringerPlus</i> , 2016, 5, 1033.	1.2	5
124	Different Prognostic Implications of Residual Disease After Neoadjuvant Treatment: Impact of Ki 67 and Site of Response. <i>Annals of Surgical Oncology</i> , 2016, 23, 3831-3837.	0.7	29
125	Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 323-332.	2.7	15
126	Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. <i>Cancer Research</i> , 2016, 76, 2301-2313.	0.4	509

#	ARTICLE	IF	CITATIONS
127	Etirinotecan pegol for the treatment of breast cancer. Expert Opinion on Pharmacotherapy, 2016, 17, 727-734.	0.9	2
128	A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Cell, 2016, 167, 260-274.e22.	13.5	376
129	Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer. Breast Cancer: Basic and Clinical Research, 2016, 10, BCBCR.S39615.	0.6	36
130	Translating neoadjuvant therapy into survival benefits: one size does not fit all. Nature Reviews Clinical Oncology, 2016, 13, 566-579.	12.5	38
131	High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy. Molecular Oncology, 2016, 10, 138-147.	2.1	76
132	Phase 1b/2 trial of BI 836845, an insulin-like growth factor (IGF) ligand-neutralizing antibody, combined with exemestane (Ex) and everolimus (Ev) in hormone receptor-positive (HR+) locally advanced or metastatic breast cancer (BC): primary phase 1b results.. Journal of Clinical Oncology, 2016, 34, 530-530.	0.8	4
133	Prognostic and therapeutic implications of fibroblast growth factor receptors (FGFRs) 1 and 2 gene amplifications in patients (pts) with advanced breast cancer (ABC).. Journal of Clinical Oncology, 2016, 34, 537-537.	0.8	2
134	HER2-positive metastatic breast cancer: first-line treatment. , 2016, , 51-69.		0
135	Clonality of PIK3CA mutations (mut) and efficacy of PI3K/AKT/mTOR inhibitors (PAMi) in patients (pts) with metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2016, 34, 528-528.	0.8	3
136	ARB: Phase II window of opportunity study of short-term preoperative treatment with enzalutamide in ER-positive and triple-negative breast cancer.. Journal of Clinical Oncology, 2016, 34, TPS619-TPS619.	0.8	1
137	Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials, 2015, 16, 575.	0.7	28
138	Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology, The, 2015, 16, 1556-1568.	5.1	79
139	Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nature Communications, 2015, 6, 8839.	5.8	605
140	High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab. Clinical Cancer Research, 2015, 21, 569-576.	3.2	71
141	Gene expression-based classifications of fibroadenomas and phyllodes tumours of the breast. Molecular Oncology, 2015, 9, 1081-1090.	2.1	39
142	Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer. New England Journal of Medicine, 2015, 372, 724-734.	13.9	1,658
143	PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Science Translational Medicine, 2015, 7, 283ra51.	5.8	276
144	Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane. Journal of Clinical Oncology, 2015, 33, 594-601.	0.8	365

#	ARTICLE	IF	CITATIONS
145	Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1700-1710.	5.1	108
146	Influencing cancer treatment. <i>Lancet Oncology</i> , The, 2015, 16, 1591-1593.	5.1	2
147	Phase III trial of etirinotecan pegol (EP) versus Treatment of Physician's Choice (TPC) in patients (pts) with advanced breast cancer (aBC) whose disease has progressed following anthracycline (A), taxane (T) and capecitabine (C): The BEACON study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1001-1001.	0.8	3
148	Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 1003-1003.	0.8	101
149	A randomized phase III study of vinflunine versus an alkylating agent of physician's choice in metastatic breast cancer (MBC) previously treated with or resistant to an anthracycline, a taxane, an antimetabolite and a vinca-alkaloid.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1031-1031.	0.8	6
150	HER2 quantification by mass spectrometry compared to IHC or ISH in predicting clinical benefit from anti-HER2 therapy in HER2-positive breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 605-605.	0.8	1
151	Survival in triple-negative breast cancer (TNBC): Evidence from the SEER database 2010-2011.. <i>Journal of Clinical Oncology</i> , 2015, 33, e12075-e12075.	0.8	2
152	HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS641-TPS641.	0.8	3
153	MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. <i>Oncotarget</i> , 2015, 6, 37269-37280.	0.8	135
154	Impact of locoregional therapy among women 70 years or older with early stage hormone receptor positive breast cancer: A population based study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 573-573.	0.8	0
155	Weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) vs gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC) in a phase 2/3 trial (tnAcity).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS1106-TPS1106.	0.8	0
156	Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	178
157	Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive, First-Line Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3753-3761.	0.8	296
158	Effect of p95HER2/611CTF on the Response to Trastuzumab and Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	36
159	Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 553-561.	1.1	174
160	The Fibroblast Growth Factor Receptor: A New Potential Target for the Treatment of Breast Cancer. <i>Current Breast Cancer Reports</i> , 2014, 6, 51-58.	0.5	2
161	Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3626-3633.	0.8	118
162	A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: An analysis of the ATHENA trial. <i>Breast</i> , 2014, 23, 656-662.	0.9	42

#	ARTICLE	IF	CITATIONS
163	Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: The role of massively parallel sequencing. <i>Molecular Oncology</i> , 2014, 8, 150-158.	2.1	37
164	New approach to cancer therapy based on a molecularly defined cancer classification. <i>Ca-A Cancer Journal for Clinicians</i> , 2014, 64, 70-74.	157.7	22
165	Trastuzumab emtansine (T-DM1) plus capecitabine (X) in patients with HER2-positive MBC: MO28230 TRAX-HER2 phase 1 results.. <i>Journal of Clinical Oncology</i> , 2014, 32, 606-606.	0.8	2
166	Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): A pooled analysis by HER2 and ER status.. <i>Journal of Clinical Oncology</i> , 2014, 32, 631-631.	0.8	2
167	Correlation of high levels of HER2 measured by multiplex mass spectrometry with increased overall survival in patients treated with anti-HER2-based therapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 649-649.	0.8	1
168	FINESSE: An open, three-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or nonamplified estrogen receptor-positive metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS1134-TPS1134.	0.8	2
169	tnAcity: A phase II/III trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) versus gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS1146-TPS1146.	0.8	2
170	A phase II randomized, double-blind, placebo-controlled multicenter trial evaluating the efficacy and safety of enzalutamide in combination with exemestane in estrogen or progesterone receptor-positive and HER2-normal advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS653-TPS653.	0.8	0
171	Targeting HSP90 in breast cancer: Enchant-1 (NCT01677455) phase 2 proof of concept study of ganetespib in first-line treatment of women with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS665-TPS665.	0.8	1
172	Incorporation of FGFR1 and FGFR2 amplification status determination in routine molecular prescreening for targeted therapies.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11105-11105.	0.8	0
173	Impact of marital status on prognostic outcome of women with breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 594-594.	0.8	1
174	Effect of age and tumor size on prognostic outcome of women with breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 592-592.	0.8	0
175	Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): A pooled analysis by HER2 and ER status.. <i>Journal of Clinical Oncology</i> , 2014, 32, 137-137.	0.8	0
176	Use of Pertuzumab for the Treatment of HER2-Positive Metastatic Breast Cancer. <i>Advances in Therapy</i> , 2013, 30, 645-658.	1.3	21
177	Contribution of ADAMTS1 as a tumor suppressor gene in human breast carcinoma. Linking its tumor inhibitory properties to its proteolytic activity on nidogenâ€1 and nidogenâ€2. <i>International Journal of Cancer</i> , 2013, 133, 2315-2324.	2.3	34
178	Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004. <i>Clinical Cancer Research</i> , 2013, 19, 1884-1893.	3.2	38
179	Bone metastases: Causes, consequences and therapeutic opportunities. <i>European Journal of Cancer, Supplement</i> , 2013, 11, 254-256.	2.2	7
180	Multidisciplinary approach to breast cancer diagnosed during pregnancy: Maternal and neonatal outcomes. <i>Breast</i> , 2013, 22, 515-519.	0.9	22

#	ARTICLE	IF	CITATIONS
181	Adjuvant bevacizumab: positive data from a negative trial. <i>Lancet Oncology</i> , The, 2013, 14, 910-911.	5.1	2
182	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 <i>Lancet Oncology</i> , The, 2013, 14, 461-471.	5.1	849
183	Circulating tumour cells and cell-free DNA as tools for managing breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 377-389.	12.5	164
184	Implication of breast cancer phenotype for patients with leptomeningeal carcinomatosis. <i>Breast</i> , 2013, 22, 19-23.	0.9	27
185	Bevacizumab in advanced breast cancer. <i>Anti-Cancer Drugs</i> , 2013, 24, 975-979.	0.7	0
186	Cardiac Tolerability of Pertuzumab Plus Trastuzumab Plus Docetaxel in Patients With HER2-Positive Metastatic Breast Cancer in CLEOPATRA: A Randomized, Double-blind, Placebo-Controlled Phase III Study. <i>Oncologist</i> , 2013, 18, 257-264.	1.9	137
187	Reply to A. Ocana et al. <i>Journal of Clinical Oncology</i> , 2013, 31, 1253-1254.	0.8	0
188	Lkb1 Loss Promotes Tumor Progression of BRAFV600E-Induced Lung Adenomas. <i>PLoS ONE</i> , 2013, 8, e66933.	1.1	11
189	A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: Subgroup analyses.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1049-1049.	0.8	8
190	Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: A phase III, open-label, randomized study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1050-1050.	0.8	4
191	Phase I dose-escalation, open-label study of HSP990 administered orally in adult patients with advanced solid malignancies.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2561-2561.	0.8	2
192	Phase III trial of non-pegylated liposomal doxorubicin (M) in combination with trastuzumab (T) and paclitaxel (P) in HER2+ metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 517-517.	0.8	4
193	Is the proportion of patients with synchronous stage IV breast cancer surviving > 2 years increasing over time?. <i>Journal of Clinical Oncology</i> , 2013, 31, 524-524.	0.8	1
194	A prognostic factor (PF) index for overall survival in a HER2-negative endocrine-resistant metastatic breast cancer (MBC) population: Analysis from the ATHENA trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 555-555.	0.8	4
195	The ENCHANT-1 trial (NCT01677455): An open label multicenter phase II proof of concept study evaluating first-line ganetespib monotherapy in women with metastatic HER2-positive or triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS1136-TPS1136.	0.8	1
196	HER2-Positive Metastatic Breast Cancer: First-Line Treatment. , 2013, , 43-60.		0
197	PAM50 HER2-enriched (HER2E) phenotype as a predictor of early-response to neoadjuvant lapatinib plus trastuzumab in stage I to IIIA HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS665-TPS665.	0.8	0
198	Early prediction of efficacy of endocrine therapy in breast cancer (BC): Pilot study and validation with 18F fluoroestradiol (18F-FES) PET/CT.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS649-TPS649.	0.8	0

#	ARTICLE	IF	CITATIONS
199	Quality of life (QoL) and content validity in objective tumor response.. Journal of Clinical Oncology, 2013, 31, 1055-1055.	0.8	0
200	Final results of a phase II trial of trabectedin (T) in patients with hormone receptor-positive, HER2-negative advanced breast cancer, according to xeroderma pigmentosum gene (XPG) expression.. Journal of Clinical Oncology, 2013, 31, 547-547.	0.8	1
201	Incidence and characteristics of breast cancer following a diagnosis of ductal carcinoma in situ.. Journal of Clinical Oncology, 2013, 31, 1131-1131.	0.8	0
202	Molecular Pathways: Targeting Hsp90â€”Who Benefits and Who Does Not. Clinical Cancer Research, 2012, 18, 4508-4513.	3.2	56
203	Advances in First-Line Treatment for Patients with HER-2+ Metastatic Breast Cancer. Oncologist, 2012, 17, 631-644.	1.9	31
204	Drug Interaction Potential of Trastuzumab Emtansine (T-DM1) Combined with Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer. Current Drug Metabolism, 2012, 13, 911-922.	0.7	41
205	Acknowledgements. Expert Review of Anticancer Therapy, 2012, 12, 1369-1369.	1.1	0
206	First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study. Journal of Clinical Oncology, 2012, 30, 921-929.	0.8	244
207	Progress Against Solid Tumors in Danger: The Metastatic Breast Cancer Example. Journal of Clinical Oncology, 2012, 30, 3444-3447.	0.8	18
208	Small-Cell Cancer of the Breast: What Is the Optimal Treatment? A Report and Review of Outcomes. Clinical Breast Cancer, 2012, 12, 287-292.	1.1	22
209	Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2â€”Positive Breast Cancer. Journal of Clinical Oncology, 2012, 30, 1594-1600.	0.8	221
210	PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition. Cancer Discovery, 2012, 2, 1036-1047.	7.7	507
211	Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer. Cancer Treatment Reviews, 2012, 38, 143-151.	3.4	40
212	Docetaxel combined with targeted therapies in metastatic breast cancer. Cancer Treatment Reviews, 2012, 38, 387-396.	3.4	14
213	Safety of bevacizumab in metastatic breast cancer patients undergoing surgery. European Journal of Cancer, 2012, 48, 475-481.	1.3	23
214	Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. New England Journal of Medicine, 2012, 366, 109-119.	18.9	2,155
215	Circulating tumour cells in early breast cancer. Lancet Oncology, The, 2012, 13, e370.	5.1	2
216	A roadmap for accelerated drug approval in breast cancer?. Lancet Oncology, The, 2012, 13, 850-851.	5.1	1

#	ARTICLE	IF	CITATIONS
217	Potential clinical applications of halichondrins in breast cancer and other neoplasms. <i>Breast Cancer: Targets and Therapy</i> , 2012, 4, 9.	1.0	2
218	Do we need biomarkers to predict the benefit of adding adjuvant taxanes for treatment of breast cancer?. <i>Breast Cancer Research</i> , 2012, 14, 104.	2.2	5
219	The use of bevacizumab among women with metastatic breast cancer: A survey on clinical practice and the ongoing controversy. <i>Cancer</i> , 2012, 118, 2780-2786.	2.0	24
220	Beyond taxanes: the next generation of microtubule-targeting agents. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 821-830.	1.1	44
221	Pregnancy after treatment of breast cancer in young women does not adversely affect the prognosis. <i>Breast</i> , 2012, 21, 272-275.	0.9	21
222	Breast cancer and HSP90 inhibitors: Is there a role beyond the HER2-positive subtype?. <i>Breast</i> , 2012, 21, 604-607.	0.9	20
223	PI3K pathway (PI3Kp) dysregulation and response to pan-PI3K/AKT/mTOR/dual PI3K-mTOR inhibitors (PI3Kpi) in metastatic breast cancer (MBC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2012, 30, 509-509.	0.8	3
224	Adverse events with pertuzumab and trastuzumab: Evolution during treatment with and without docetaxel in CLEOPATRA.. <i>Journal of Clinical Oncology</i> , 2012, 30, 597-597.	0.8	7
225	Quality of life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 598-598.	0.8	9
226	A phase II trial of trabectedin (T) in patients with hormone receptor-positive, HER2-negative advanced breast cancer, according to xeroderma pigmentosum gene (XPG) expression.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS652-TPS652.	0.8	1
227	Presentation and treatment of HER2-positive metastatic breast cancer patients already treated with adjuvant trastuzumab.. <i>Journal of Clinical Oncology</i> , 2012, 30, 619-619.	0.8	0
228	Prognostic significance of PI3K pathway (PI3Kp) dysregulation in metastatic breast cancer (MBC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2012, 30, 566-566.	0.8	0
229	Analysis of the intratumoral heterogeneity of PIK3CA mutant alleles in breast cancer (BC): Implications for the luminal (LUM) phenotype.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10511-10511.	0.8	0
230	Phase III open-label, randomized, multicenter study of NKTR-102 versus treatment of physician's choice (TPC) in patients (pts) with locally recurrent or metastatic breast cancer (MBC) previously treated with an anthracycline, a taxane, and capecitabine (ATC).. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS1140-TPS1140.	0.8	0
231	Impact of surgery and radiation of the primary among women with de novo stage IV breast cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1032-1032.	0.8	0
232	Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancer. <i>Future Oncology</i> , 2011, 7, 355-364.	1.1	5
233	HER2 and hormone receptor-positive breast cancer—blocking the right target. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 307-311.	12.5	28
234	Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. <i>Lancet, The</i> , 2011, 377, 914-923.	6.3	949

#	ARTICLE	IF	CITATIONS
235	Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer. <i>OncoTargets and Therapy</i> , 2011, 4, 185.	1.0	10
236	Outcome of patients following hepatic resection for metastatic cutaneous and ocular melanoma. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2011, 18, 268-275.	1.4	23
237	Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 ⁺ breast cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 3761-3766.	3.3	291
238	Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain. <i>Clinical and Translational Oncology</i> , 2010, 12, 692-700.	1.2	15
239	Phase III Trials of Eribulin Mesylate (E7389) in Extensively Pretreated Patients With Locally Recurrent or Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2010, 10, 160-163.	1.1	101
240	Methylthioadenosine (MTA) inhibits melanoma cell proliferation and in vivotumor growth. <i>BMC Cancer</i> , 2010, 10, 265.	1.1	35
241	Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3239-3247.	0.8	812
242	Intensive Loading Dose of Trastuzumab Achieves Higher-Than-Steadyâ€“State Serum Concentrations and Is Well Tolerated. <i>Journal of Clinical Oncology</i> , 2010, 28, 960-966.	0.8	37
243	Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 1131-1137.	0.8	214
244	Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 1138-1144.	0.8	593
245	Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine. <i>Journal of Clinical Oncology</i> , 2010, 28, 3922-3928.	0.8	194
246	Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study. <i>Clinical Cancer Research</i> , 2009, 15, 307-314.	3.2	65
247	Risk of Venous Thromboembolism With Bevacizumab in Cancer Patients. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 1434.	3.8	7
248	How to Treat Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Amplified Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5492-5494.	0.8	21
249	Prognostic and predictive factors and genetic analysis of early breast cancer. <i>Clinical and Translational Oncology</i> , 2009, 11, 634-642.	1.2	7
250	Hepatic Resection for Liver Metastases as Part of the â€œOncosurgicalâ€“Treatment of Metastatic Breast Cancer. <i>Annals of Surgical Oncology</i> , 2008, 15, 2804-2810.	0.7	75
251	Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2007, 99, 628-638.	3.0	769
252	Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2007, 14, 221-232.	1.6	142

#	ARTICLE	IF	CITATIONS
253	Targeting the Microtubules in Breast Cancer Beyond Taxanes: The Etoposides. <i>Oncologist</i> , 2007, 12, 271-280.	1.9	132
254	Prognostic factors for disease-free survival in patients with T3-4 or N+ rectal cancer treated with preoperative chemoradiation therapy, surgery, and intraoperative irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 1122-1128.	0.4	67
255	Preoperative chemoradiation with oral tegafur within a multidisciplinary therapeutic approach in patients with T3-4 rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 1378-1384.	0.4	13
256	Paclitaxel, Cisplatin, and Vinorelbine Combination Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 299-303.	0.6	4
257	Front-Line Paclitaxel/Cisplatin-Based Chemotherapy in Brain Metastases from Non-Small-Cell Lung Cancer. <i>Oncology</i> , 2003, 64, 28-35.	0.9	126
258	Combined Irinotecan, Oxaliplatin and 5-Fluorouracil in Patients with Advanced Colorectal Cancer. <i>Oncology</i> , 2002, 63, 254-265.	0.9	21